As artificial intelligence (AI) and digital tools rapidly evolve, they are poised to reshape biopharmaceutical cell line development and subsequent manufacturing, overcoming inefficiencies in expression, scalability, and production.
The webinar will discuss how the Cytiva™ cell culture media platform and Asimov’s CHO Edge system routinely deliver high-titer clones (8–11 g/L) in 14 weeks for monoclonal and multispecific antibodies. The speakers will share a data-driven vision for the future of biologics production and discuss progress toward holistic optimal design of cell lines, genetic systems, and bioprocesses.
This webinar is ideal for professionals involved in biologics development and manufacturing, including:
Register for free to get video access
Zhou Jiang
Director, Cell Culture Services
Zhou Jiang, PhD, is Director of Cell Culture Media Services at Cytiva, where he spearheads innovation in custom cell culture solutions through close collaboration with biopharmaceutical customers. With over 18 years of industrial experience, Zhou’s career has spanned cell line engineering, media formulation and manufacturing, and upstream process development. He has made contributions to the advancement of a wide range of therapeutic modalities, including monoclonal antibodies, recombinant proteins, vaccines, viral vectors, and antibody-drug conjugates.
Imroz Ghangas
Vice President, Commercial Sales
As Vice President of Commercial Sales at Asimov, Imroz Ghangas and his team drive partnerships to advance the company’s genetic design platform and AI capabilities. With over 25 years in biotech, Imroz has evolved from process development scientist to commercial leader, bridging technical innovation with scalable solutions. His expertise spans bioprocess development and platform integration, with deep knowledge of biomanufacturing workflows from gene to drug product. He leverages his technical foundation to accelerate the adoption of next-generation bioprocessing technologies.
